利bomunyl治疗儿童病毒性支气管哮喘的临床免疫效果

E. B. Belan, E. M. Nikiforova, T. E. Zayachnikova, L. N. Shishimorov, O. V. Magnitskaya
{"title":"利bomunyl治疗儿童病毒性支气管哮喘的临床免疫效果","authors":"E. B. Belan, E. M. Nikiforova, T. E. Zayachnikova, L. N. Shishimorov, O. V. Magnitskaya","doi":"10.19163/2307-9266-2020-8-3-160-168","DOIUrl":null,"url":null,"abstract":"The aim of the study is to research the effects of immunostimulant Ribomunyl in virus-induced bronchial asthma (VBA) children.Materials and methods. 14 virus-induced bronchial asthma (VBA) children were agministrated with immunostimulant Ribomunyl as a part of complex therapy in a 18-month trial (3 cycles of treatment). The comparison group consisted of 16 patients who received only standard therapy for bronchial asthma. At the end of the study, against the background of basic BA therapy, the following parameters were estimated: the frequency of acute respiratory viral infections (ARVI), the need for antibacterial therapy, the frequency of IgG to respiratory-syncytial virus (RSV) prevalence, the serum level dynamics of total IgE, IFN-γ, interleukin-4 (IL-4), interferon gamma (IFN-γ).Results. The inclusion of Ribomunyl into the basic therapy complex in virus-induced bronchial asthma (VBA) children, made it possible to reduce the need for the VBA basic therapy complex by 50% and by 12,5% (р=0,0279). At the same time, as for the frequency of acute respiratory viral infections (ARVI), there was a comparable decrease in both groups, but in the main group the number of cases requiring antibiotic therapy decreased from 78.6% to 42.9% (p=0.0199). The inclusion of Ribomunyl into the basic therapy complex resulted in the decrease of the total IgE serum level; in the patients with the initial presence of IgG to the respiratory syncytial virus (RSV), the IL-4 level decreased and the IFN-γ level increased.Conclusion. Ribomunyl improves the treatment of virus-induced bronchial asthma (VBA) children, herewith the dynamics of immunological indicators is more in RSV-seropositive patients.","PeriodicalId":20025,"journal":{"name":"Pharmacy & Pharmacology","volume":"73 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2020-12-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"CLINICAL-IMMUNOLOGICAL EFFECTIVENESS OF RIBOMUNYL IN CHILDREN WITH VIRUS-INDUCED BRONCHIAL ASTHMA\",\"authors\":\"E. B. Belan, E. M. Nikiforova, T. E. Zayachnikova, L. N. Shishimorov, O. V. Magnitskaya\",\"doi\":\"10.19163/2307-9266-2020-8-3-160-168\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The aim of the study is to research the effects of immunostimulant Ribomunyl in virus-induced bronchial asthma (VBA) children.Materials and methods. 14 virus-induced bronchial asthma (VBA) children were agministrated with immunostimulant Ribomunyl as a part of complex therapy in a 18-month trial (3 cycles of treatment). The comparison group consisted of 16 patients who received only standard therapy for bronchial asthma. At the end of the study, against the background of basic BA therapy, the following parameters were estimated: the frequency of acute respiratory viral infections (ARVI), the need for antibacterial therapy, the frequency of IgG to respiratory-syncytial virus (RSV) prevalence, the serum level dynamics of total IgE, IFN-γ, interleukin-4 (IL-4), interferon gamma (IFN-γ).Results. The inclusion of Ribomunyl into the basic therapy complex in virus-induced bronchial asthma (VBA) children, made it possible to reduce the need for the VBA basic therapy complex by 50% and by 12,5% (р=0,0279). At the same time, as for the frequency of acute respiratory viral infections (ARVI), there was a comparable decrease in both groups, but in the main group the number of cases requiring antibiotic therapy decreased from 78.6% to 42.9% (p=0.0199). The inclusion of Ribomunyl into the basic therapy complex resulted in the decrease of the total IgE serum level; in the patients with the initial presence of IgG to the respiratory syncytial virus (RSV), the IL-4 level decreased and the IFN-γ level increased.Conclusion. Ribomunyl improves the treatment of virus-induced bronchial asthma (VBA) children, herewith the dynamics of immunological indicators is more in RSV-seropositive patients.\",\"PeriodicalId\":20025,\"journal\":{\"name\":\"Pharmacy & Pharmacology\",\"volume\":\"73 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2020-12-21\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pharmacy & Pharmacology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.19163/2307-9266-2020-8-3-160-168\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmacy & Pharmacology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.19163/2307-9266-2020-8-3-160-168","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

本研究的目的是研究免疫刺激剂利bomunyl对儿童病毒性支气管哮喘(VBA)的作用。材料和方法。在一项为期18个月(3个治疗周期)的试验中,14名病毒诱导支气管哮喘(VBA)儿童服用免疫刺激剂利博门尼作为综合治疗的一部分。对照组由16例仅接受支气管哮喘标准治疗的患者组成。研究结束时,在基础BA治疗的背景下,估计了以下参数:急性呼吸道病毒感染(ARVI)的频率,抗菌治疗的需要,IgG到呼吸道合胞病毒(RSV)的流行频率,血清总IgE、IFN-γ、白细胞介素-4 (IL-4)、干扰素γ (IFN-γ)的水平动态。将利bomunyl纳入病毒诱导支气管哮喘(VBA)儿童的基础治疗复合体中,可以将VBA基础治疗复合体的需求减少50%和12.5% (r = 0.0279)。同时,急性呼吸道病毒感染(ARVI)的频率在两组中均有相当的下降,但在主组中,需要抗生素治疗的病例数从78.6%下降到42.9% (p=0.0199)。利bomunyl加入基础治疗复合物导致血清总IgE水平下降;呼吸道合胞病毒(RSV) IgG初始存在时,IL-4水平降低,IFN-γ水平升高。利bomunyl改善了儿童病毒性支气管哮喘(VBA)的治疗效果,在rsv血清阳性患者中免疫指标的动态变化更多。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
CLINICAL-IMMUNOLOGICAL EFFECTIVENESS OF RIBOMUNYL IN CHILDREN WITH VIRUS-INDUCED BRONCHIAL ASTHMA
The aim of the study is to research the effects of immunostimulant Ribomunyl in virus-induced bronchial asthma (VBA) children.Materials and methods. 14 virus-induced bronchial asthma (VBA) children were agministrated with immunostimulant Ribomunyl as a part of complex therapy in a 18-month trial (3 cycles of treatment). The comparison group consisted of 16 patients who received only standard therapy for bronchial asthma. At the end of the study, against the background of basic BA therapy, the following parameters were estimated: the frequency of acute respiratory viral infections (ARVI), the need for antibacterial therapy, the frequency of IgG to respiratory-syncytial virus (RSV) prevalence, the serum level dynamics of total IgE, IFN-γ, interleukin-4 (IL-4), interferon gamma (IFN-γ).Results. The inclusion of Ribomunyl into the basic therapy complex in virus-induced bronchial asthma (VBA) children, made it possible to reduce the need for the VBA basic therapy complex by 50% and by 12,5% (р=0,0279). At the same time, as for the frequency of acute respiratory viral infections (ARVI), there was a comparable decrease in both groups, but in the main group the number of cases requiring antibiotic therapy decreased from 78.6% to 42.9% (p=0.0199). The inclusion of Ribomunyl into the basic therapy complex resulted in the decrease of the total IgE serum level; in the patients with the initial presence of IgG to the respiratory syncytial virus (RSV), the IL-4 level decreased and the IFN-γ level increased.Conclusion. Ribomunyl improves the treatment of virus-induced bronchial asthma (VBA) children, herewith the dynamics of immunological indicators is more in RSV-seropositive patients.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
USE OF SEQUENCING METHODS FOR SPECIES IDENTIFICATION EXEMPLIFIED BY PHYLOGENETIC RELATIONSHIPS WITHIN GENUS HEDYSARUM L. CLINICAL AND ECONOMIC JUSTIFICATION OF SOFTWARE SCREENING PERFORMANCE OF COLORECTAL CANCER AT THE REGION LEVEL STUDY OF CLINICAL AND PATHOGENETIC EFFECTS OF ANTI-VIRAL DRUG BASED ON FAVIPIRAVIR IN COMORBID PATIENTS WITH COVID-19 AT THE OUTPATIENT STAGE OF TREATMENT ANALYSIS OF THE PERSONNEL’S CONSISTENT READINESS FOR CHANGES AS ILLUSTRATED BY THE EXAMPLE OF AN EXPORT-ORIENTED BIOTECHNOLOGICAL ENTERPRISE DEVELOPMENT OF PERORAL HYPOLIPIDEMIC FORMULATION BASED ON SULFATED ARABINOGALACTAN IN THE FORM OF POTASSIUM SALT
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1